Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Treatment of patients with neurotrophic keratitis stages 2 and 3 with plasma rich in growth factors (PRGF-Endoret) eye-drops

Treatment of patients with neurotrophic keratitis stages 2 and 3 with plasma rich in growth... Int Ophthalmol (2018) 38:1193–1204 https://doi.org/10.1007/s10792-017-0582-7 ORIGINAL PAPER Treatment of patients with neurotrophic keratitis stages 2 and 3 with plasma rich in growth factors (PRGF-Endoret) eye-drops . . . Ronald Mauricio Sanchez-Avila Jesus Merayo-Lloves Ana Cristina Riestra . . . Luis Fernandez-Vega Cueto Eduardo Anitua Leire Begona Francisco Muruzabal Gorka Orive Received: 26 August 2016 / Accepted: 5 June 2017 / Published online: 15 June 2017 Springer Science+Business Media B.V. 2017 Abstract and Visual Analogue Scale (VAS) were also evaluated Purpose To provide preliminary data about efficacy before and after treatment with PRGF. The influence and safety of plasma rich in growth factors (PRGF) of some patients’ clinical variables on results was eye-drops in neurotrophic keratitis (NK) and to assessed. Safety assessment was also performed analyze the possible influence of certain variables on reporting all adverse events. treatment outcomes. Results Thirty-eight treated eyes in a total of thirty- Methods This retrospective study included patients one patients were evaluated, of which five cases had no with stages 2–3 of NK treated with PRGF eye-drops. prior response to autologous serum treatment. Most Primary endpoint was the resolution time of corneal cases (97.4%) achieved the complete resolution of ulcer defect. Outcome measures including http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png International Ophthalmology Springer Journals

Treatment of patients with neurotrophic keratitis stages 2 and 3 with plasma rich in growth factors (PRGF-Endoret) eye-drops

Download PDF
12 pages

Loading next page...
 
/lp/springer_journal/treatment-of-patients-with-neurotrophic-keratitis-stages-2-and-3-with-LKs1ZU4Fpz
Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer Science+Business Media B.V.
Subject
Medicine & Public Health; Ophthalmology
ISSN
0165-5701
eISSN
1573-2630
DOI
10.1007/s10792-017-0582-7
pmid
28620707
Publisher site
See Article on Publisher Site

Abstract

Int Ophthalmol (2018) 38:1193–1204 https://doi.org/10.1007/s10792-017-0582-7 ORIGINAL PAPER Treatment of patients with neurotrophic keratitis stages 2 and 3 with plasma rich in growth factors (PRGF-Endoret) eye-drops . . . Ronald Mauricio Sanchez-Avila Jesus Merayo-Lloves Ana Cristina Riestra . . . Luis Fernandez-Vega Cueto Eduardo Anitua Leire Begona Francisco Muruzabal Gorka Orive Received: 26 August 2016 / Accepted: 5 June 2017 / Published online: 15 June 2017 Springer Science+Business Media B.V. 2017 Abstract and Visual Analogue Scale (VAS) were also evaluated Purpose To provide preliminary data about efficacy before and after treatment with PRGF. The influence and safety of plasma rich in growth factors (PRGF) of some patients’ clinical variables on results was eye-drops in neurotrophic keratitis (NK) and to assessed. Safety assessment was also performed analyze the possible influence of certain variables on reporting all adverse events. treatment outcomes. Results Thirty-eight treated eyes in a total of thirty- Methods This retrospective study included patients one patients were evaluated, of which five cases had no with stages 2–3 of NK treated with PRGF eye-drops. prior response to autologous serum treatment. Most Primary endpoint was the resolution time of corneal cases (97.4%) achieved the complete resolution of ulcer defect. Outcome measures including

Journal

International Ophthalmology – Springer Journals

Published: Jun 15, 2017

References

  • Diagnosis and management of neurotrophic keratitis
    Sacchetti, M; Lambiase, A
  • Neurotrophic keratitis
    Bonini, S; Rama, P; Olzi, D; Lambiase, A
  • The molecular basis of neurotrophic keratitis
    Cavanagh, HD; Colley, AM
  • Management of neurotrophic keratopathy
    Lambiase, A; Rama, P; Aloe, L; Bonini, S
  • Application of umbilical cord serum eyedrops for the treatment of neurotrophic keratitis
    Yoon, KC; You, IC; Im, SK; Jeong, TS; Park, YG; Choi, J
  • Targeting growth factor supply in keratopathy treatment: comparison between maternal peripheral blood and cord blood as sources for the preparation of topical eye drops
    Versura, P; Buzzi, M; Giannaccare, G; Terzi, A; Fresina, M; Velati, C; Campos, EC
  • Cord blood serum-based eye drops: the impact of donor haematological and obstetric factors on the variability of epidermal growth factor levels
    Versura, P; Buzzi, M; Giannaccare, G; Grillini, M; Terzi, A; Pagliaro, P; Campos, EC
  • Comparison of corneal epitheliotrophic capacity among different human blood-derived preparations
    Shen, EP; Hu, F-R; Lo, S-C; Chen, Y-M; Sun, Y-C; Lin, C-T; Chen, W-L
  • Autologous serum 50% eyedrops in the treatment of persistent corneal epithelial defects
    Jeng, BH; Dupps, WJ
  • Autologous serum application in the treatment of neurotrophic keratopathy
    Matsumoto, Y; Dogru, M; Goto, E; Ohashi, Y; Kojima, T; Ishida, R; Tsubota, K
  • Morphogen and proinflammatory cytokine release kinetics from PRGF-Endoret fibrin scaffolds: evaluation of the effect of leukocyte inclusion
    Anitua, E; Zalduendo, MM; Prado, R; Alkhraisat, MH; Orive, G
  • Leukocyte inclusion within a platelet rich plasma-derived fibrin scaffold stimulates a more pro-inflammatory environment and alters fibrin properties
    Anitua, E; Zalduendo, M; Troya, M; Padilla, S; Orive, G
  • Plasma rich in growth factors (PRGF-Endoret) stimulates proliferation and migration of primary keratocytes and conjunctival fibroblasts and inhibits and reverts TGF-beta1-Induced myodifferentiation
    Anitua, E; Sanchez, M; Merayo-Lloves, J; Fuente, M; Muruzabal, F; Orive, G
  • Plasma rich in growth factors (PRGF-Endoret) stimulates corneal wound healing and reduces haze formation after PRK surgery
    Anitua, E; Muruzabal, F; Alcalde, I; Merayo-Lloves, J; Orive, G
  • Effects of heat-treatment on plasma rich in growth factors-derived autologous eye drop
    Anitua, E; Muruzabal, F; Fuente, M; Merayo-Lloves, J; Orive, G
  • Biological stability of plasma rich in growth factors eye drops after storage of 3 months
    Anitua, E; Muruzabal, F; Pino, A; Merayo-Lloves, J; Orive, G
  • Infiltration of plasma rich in growth factors enhances in vivo angiogenesis and improves reperfusion and tissue remodeling after severe hind limb ischemia
    Anitua, E; Pelacho, B; Prado, R; Aguirre, JJ; Sánchez, M; Padilla, S; Aranguren, XL; Abizanda, G; Collantes, M; Hernandez, M; Perez-Ruiz, A; Peñuelas, I; Orive, G; Prosper, F
  • Molecular basis of anti-inflammatory action of platelet-rich plasma on human chondrocytes: mechanisms of NF-kB inhibition via HGF
    Bendinelli, P; Matteucci, E; Dogliotti, G; Corsi, MM; Banfi, G; Maroni, P; Desiderio, MA
  • Antibacterial effect of plasma rich in growth factors (PRGF®-Endoret®) against Staphylococcus aureus and Staphylococcus epidermidis strains
    Anitua, E; Alonso, R; Girbau, C; Aguirre, JJ; Muruzabal, F; Orive, G
  • Plasma components and platelet activation are essential for the antimicrobial properties of autologous platelet-rich plasma: an in vitro study
    Drago, L; Bortolin, M; Vassena, C; Romanò, CL; Taschieri, S; Fabbro, M
  • Treatment of neurotrophic keratopathy with substance-P-derived peptide (FGLM) and insulin-like growth factor I
    Chikama, TI; Fukuda, K; Morishige, N; Nishida, T
  • Topical treatment with nerve growth factor for neurotrophic keratitis
    Bonini, S; Lambiase, A; Rama, P; Caprioglio, G; Aloe, L
  • Inflammation and axon regeneration
    Benowitz, LI; Popovich, PG
  • Corneal nerves in health and disease
    Shaheen, BS; Bakir, M; Jain, S
  • Autologous serum eye drops for ocular surface disorders
    Geerling, G; Maclennan, S; Hartwing, D
  • Platelet rich plasma (PRP) enhances anabolic gene expression patterns in flexor digitorum superficialis tendons
    Schnabel, LV; Mohammed, HO; Miller, BJ; McDermott, WG; Jacobson, MS; Santangelo, KS; Fortier, LA
  • Interleukin-6 and tumor necrosis factor-alpha levels in tears of patients with dry eye syndrome
    Yoon, K-C; Jeong, I-Y; Park, Y-G; Yang, S-Y
  • In vitro effects of three blood derivatives on human corneal epithelial cells
    Freire, V; Andollo, N; Etxebarria, J; Durán, JA; Morales, M-C
  • Closing regulatory gaps: new ground rules for platelet-rich plasma
    Anitua, E; Prado, R; Orive, G
  • Effects of heat-treatment on plasma rich in growth factors-derived autologous eye drop
    Anitua, E; Muruzabal, F; Fuente, M; Merayo-Lloves, J; Orive, G
  • Plasma rich in growth factors (PRGF) eye drops stimulates scarless regeneration compared to autologous serum in the ocular surface stromal fibroblasts
    Anitua, E; Fuente, M; Muruzabal, F; Riestra, A; Merayo-Lloves, J; Orive, G
  • Autologous serum and plasma rich in growth factors in ophthalmology: preclinical and clinical studies
    Anitua, E; Muruzabal, F; Tayebba, A; Riestra, A; Perez, VL; Merayo-Lloves, J; Orive, G
  • Plasma rich in growth factors for the treatment of ocular surface diseases
    Anitua, E; Muruzabal, F; Fuente, M; Merayo, J; Duran, J; Orive, G
  • Safety and efficacy of autologous plasma rich in growth factors eye drops for the treatment of evaporative dry eye
    Merayo-Lloves, J; Sanchez-Avila, RM; Riestra, AC; Anitua, E; Begona, L; Orive, G; Fernandez-Vega, L
  • Autologous plasma rich in growth factors eyedrops in refractory cases of ocular surface disorders
    Merayo-Lloves, J; Sanchez, RM; Riestra, AC; Anitua, E; Begona, L; Orive, G; Fernandez-Vega, L
  • Effect of autologous platelet-rich plasma on persistent corneal epithelial defect after infectious keratitis
    Kim, KM; Shin, Y-T; Kim, HK
  • Neurotrophic keratitis
    Semeraro, F; Forbice, E; Romano, V; Angi, M; Romano, MR; Filippelli, ME; Iorio, R; Costagliola, C
  • Topical treatment with a new matrix therapy agent (RGTA) for the treatment of corneal neurotrophic ulcers
    Aifa, A; Gueudry, J; Portmann, A; Delcampe, A; Muraine, M
  • RGTA-based matrix therapy in severe experimental corneal lesions: safety and efficacy studies
    Brignole-Baudouin, F; Warnet, JM; Barritault, D; Baudouin, C
  • Combined topical application of a regenerative agent with a bandage contact lens for the treatment of persistent epithelial defects
    Kymionis, GD; Liakopoulos, DA; Grentzelos, MA; Diakonis, VF; Klados, NE; Tsoulnaras, KI; Tsilimbaris, MK; Pallikaris, IG